Biological meaning of stage and grade in human breast cancer: Review and hypothesis Francis E. Sharkey Review Pages: 299 - 322
Tumor cell proliferation and sequential chemotherapy after partial tumor resection in C3H/HeJ mammary tumors Paul G. BraunschweigerLewis M. SchifferSergio Betancourt Report Pages: 323 - 329
Tumor-associated prostaglandins in patients with primary breast cancer: Relationship to clinical parameters Amy FultonLarry RoiMichael J. Brennan Report Pages: 331 - 337
Quantitative comparison of estradiol and progesterone receptor contents of primary and metastatic human breast tumors in relation to response to endocrine treatment R. J. B. KingJ. F. StewartJ. L. Hayward Report Pages: 339 - 346
Considerations in the design and evaluation of cytotoxic estrogens John A. KatzenellenbogenBenita S. Katzenellenbogen Scandinavian Breast Cancer Symposium Pages: 347 - 353
Nutritional aspects of the epidemiology of breast cancer F. de Waard Scandinavian Breast Cancer Symposium Pages: 355 - 361
The biology and physiology of ‘Nolvadex’ (tamoxifen) in the treatment of breast cancer John PattersonBarry FurrLinda Battersby Scandinavian Breast Cancer Symposium Pages: 363 - 374
Pharmacologic suppression of estrogens with aminoglutethimide as treatment of advanced breast carcinoma Richard J. SantenElliott BadderSamuel A. Wells Scandinavian Breast Cancer Symposium Pages: 375 - 383
Some properties of a plasminogen activating factor in human breast cancer cytosol and its relation to steroid receptors Thor Thorsen Scandinavian Breast Cancer Symposium Pages: 385 - 390
Perioperative adjuvant chemotherapy vs postoperative chemotherapy for one year Roar Nissen-MeyerHerman HøstTorsten Norin Scandinavian Breast Cancer Symposium Pages: 391 - 394
Treatment of advanced breast cancer with tamoxifen: Evaluation of the dose-response relationship at two dose levels Carsten RoseKaren TheiladeHenning T. Mouridsen Scandinavian Breast Cancer Symposium Pages: 395 - 400
Monoclonal antibodies applied to primary human breast carcinoma: Relationship to menopausal status, lymph node status, and steroid hormone receptor content Birgitte Bruun RasmussenJohn HilkensCarsten Rose Scandinavian Breast Cancer Symposium Pages: 401 - 405
Adjuvant endocrine therapy of breast cancer R. D. Rubens Scandinavian Breast Cancer Symposium Pages: 407 - 410
12 versus 6 cycles of adjuvant CMF in breast cancer Anaxagoras PapaioannouGeorge Papageorgiou Correspondence Pages: 411 - 411
12 versus 6 cycles of adjuvant CMF in breast cancer — Reply Pinuccia ValagussaGianni Bonadonna Correspondence Pages: 411 - 412
An unusual fatal marrow suppression from very brief adjuvant chemotherapy for Stage II breast cancer Alexander R. StevensJames M. Thornbery Correspondence Pages: 412 - 414
The influence of parity on estrogen and progesterone receptors in primary breast cancer Susan M. ThorpeCarsten RoseBirgitte Bruun Rasmussen Correspondence Pages: 414 - 416
